BRAF inhibitors in combination with MEK inhibitors resulted in increased tolerability and efficacy, leading to several combination therapies being improved (dabrafenib plus trametinib, vemurafenib plus cobimetinib, and encorafenib plus binimetinib) in BRAF V600E-mutant melanoma [64,65,66]. The gene discussed is MAP2K7; the disease is melanoma.